nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0397	0.061	CbGbCtD
Atomoxetine—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0373	0.0574	CbGbCtD
Atomoxetine—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0338	0.0519	CbGbCtD
Atomoxetine—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0338	0.0519	CbGbCtD
Atomoxetine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0302	0.0464	CbGbCtD
Atomoxetine—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0292	0.0448	CbGbCtD
Atomoxetine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0284	0.0436	CbGbCtD
Atomoxetine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0284	0.0436	CbGbCtD
Atomoxetine—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0283	0.0435	CbGbCtD
Atomoxetine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0257	0.0394	CbGbCtD
Atomoxetine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0257	0.0394	CbGbCtD
Atomoxetine—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0256	0.0393	CbGbCtD
Atomoxetine—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0256	0.0393	CbGbCtD
Atomoxetine—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0245	0.0377	CbGbCtD
Atomoxetine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0222	0.0341	CbGbCtD
Atomoxetine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0215	0.0331	CbGbCtD
Atomoxetine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0195	0.0299	CbGbCtD
Atomoxetine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0195	0.0299	CbGbCtD
Atomoxetine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0192	0.0295	CbGbCtD
Atomoxetine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0181	0.0277	CbGbCtD
Atomoxetine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0181	0.0277	CbGbCtD
Atomoxetine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0163	0.0251	CbGbCtD
Atomoxetine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0163	0.0251	CbGbCtD
Atomoxetine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0141	0.0217	CbGbCtD
Atomoxetine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0137	0.021	CbGbCtD
Atomoxetine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0124	0.019	CbGbCtD
Atomoxetine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0124	0.019	CbGbCtD
Atomoxetine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0119	0.0182	CbGbCtD
Atomoxetine—NPY1R—nerve—acquired immunodeficiency syndrome	0.0069	0.115	CbGeAlD
Atomoxetine—SLC6A3—nerve—acquired immunodeficiency syndrome	0.0029	0.0483	CbGeAlD
Atomoxetine—SLC6A2—nerve—acquired immunodeficiency syndrome	0.00234	0.039	CbGeAlD
Atomoxetine—SLC6A4—blood plasma—acquired immunodeficiency syndrome	0.00201	0.0335	CbGeAlD
Atomoxetine—NPY1R—blood—acquired immunodeficiency syndrome	0.00191	0.0318	CbGeAlD
Atomoxetine—NPY1R—vagina—acquired immunodeficiency syndrome	0.00177	0.0295	CbGeAlD
Atomoxetine—NPY1R—lung—acquired immunodeficiency syndrome	0.00167	0.0279	CbGeAlD
Atomoxetine—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00167	0.0278	CbGeAlD
Atomoxetine—NPY1R—nervous system—acquired immunodeficiency syndrome	0.00155	0.0258	CbGeAlD
Atomoxetine—NPY1R—central nervous system—acquired immunodeficiency syndrome	0.00149	0.0249	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—acquired immunodeficiency syndrome	0.00149	0.449	CrCbGaD
Atomoxetine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00141	0.0234	CbGeAlD
Atomoxetine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.0012	0.02	CbGeAlD
Atomoxetine—NPY1R—brain—acquired immunodeficiency syndrome	0.00119	0.0197	CbGeAlD
Atomoxetine—NPY1R—lymph node—acquired immunodeficiency syndrome	0.00115	0.0191	CbGeAlD
Atomoxetine—HTR6—nervous system—acquired immunodeficiency syndrome	0.00109	0.0182	CbGeAlD
Atomoxetine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00106	0.0177	CbGeAlD
Atomoxetine—HTR6—central nervous system—acquired immunodeficiency syndrome	0.00105	0.0175	CbGeAlD
Atomoxetine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000985	0.0164	CbGeAlD
Atomoxetine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000969	0.0161	CbGeAlD
Atomoxetine—HTR6—brain—acquired immunodeficiency syndrome	0.000834	0.0139	CbGeAlD
Atomoxetine—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000781	0.013	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—acquired immunodeficiency syndrome	0.000774	0.0129	CbGeAlD
Atomoxetine—SLC6A4—digestive system—acquired immunodeficiency syndrome	0.000773	0.0129	CbGeAlD
Atomoxetine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000749	0.0125	CbGeAlD
Atomoxetine—SLC6A4—blood—acquired immunodeficiency syndrome	0.000737	0.0123	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—acquired immunodeficiency syndrome	0.00071	0.0118	CbGeAlD
Atomoxetine—SLC6A3—lung—acquired immunodeficiency syndrome	0.000705	0.0117	CbGeAlD
Atomoxetine—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000658	0.011	CbGeAlD
Atomoxetine—SLC6A3—nervous system—acquired immunodeficiency syndrome	0.000653	0.0109	CbGeAlD
Atomoxetine—SLC6A4—lung—acquired immunodeficiency syndrome	0.000646	0.0108	CbGeAlD
Atomoxetine—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000641	0.0107	CbGeAlD
Atomoxetine—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000637	0.0106	CbGeAlD
Atomoxetine—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000633	0.0106	CbGeAlD
Atomoxetine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.000631	0.0105	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—acquired immunodeficiency syndrome	0.000628	0.0105	CbGeAlD
Atomoxetine—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000613	0.0102	CbGeAlD
Atomoxetine—CYP2C19—blood—acquired immunodeficiency syndrome	0.00061	0.0102	CbGeAlD
Atomoxetine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000607	0.0101	CbGeAlD
Atomoxetine—SLC6A4—nervous system—acquired immunodeficiency syndrome	0.000598	0.00996	CbGeAlD
Atomoxetine—HTR2A—retina—acquired immunodeficiency syndrome	0.000583	0.0097	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—acquired immunodeficiency syndrome	0.000576	0.00959	CbGeAlD
Atomoxetine—SLC6A2—lung—acquired immunodeficiency syndrome	0.000569	0.00947	CbGeAlD
Atomoxetine—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000566	0.00942	CbGeAlD
Atomoxetine—SLC6A2—nervous system—acquired immunodeficiency syndrome	0.000526	0.00877	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—acquired immunodeficiency syndrome	0.000507	0.00844	CbGeAlD
Atomoxetine—Pseudoephedrine—TNF—acquired immunodeficiency syndrome	0.000503	0.152	CrCbGaD
Atomoxetine—HTR1B—brain—acquired immunodeficiency syndrome	0.000503	0.00838	CbGeAlD
Atomoxetine—SLC6A3—brain—acquired immunodeficiency syndrome	0.000499	0.00831	CbGeAlD
Atomoxetine—HTR1D—brain—acquired immunodeficiency syndrome	0.000487	0.00811	CbGeAlD
Atomoxetine—HTR2C—brain—acquired immunodeficiency syndrome	0.000482	0.00803	CbGeAlD
Atomoxetine—SLC6A4—brain—acquired immunodeficiency syndrome	0.000457	0.00761	CbGeAlD
Atomoxetine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000409	0.00681	CbGeAlD
Atomoxetine—SLC6A2—brain—acquired immunodeficiency syndrome	0.000402	0.0067	CbGeAlD
Atomoxetine—HTR2A—blood—acquired immunodeficiency syndrome	0.00039	0.00649	CbGeAlD
Atomoxetine—SLC6A2—lymph node—acquired immunodeficiency syndrome	0.000389	0.00648	CbGeAlD
Atomoxetine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000379	0.00631	CbGeAlD
Atomoxetine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000376	0.00625	CbGeAlD
Atomoxetine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000373	0.00621	CbGeAlD
Atomoxetine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000361	0.00602	CbGeAlD
Atomoxetine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000361	0.00601	CbGeAlD
Atomoxetine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000355	0.00591	CbGeAlD
Atomoxetine—HTR2A—lung—acquired immunodeficiency syndrome	0.000342	0.00569	CbGeAlD
Atomoxetine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000316	0.00527	CbGeAlD
Atomoxetine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000305	0.00507	CbGeAlD
Atomoxetine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000293	0.00488	CbGeAlD
Atomoxetine—Fenoprofen—ALB—acquired immunodeficiency syndrome	0.000292	0.0881	CrCbGaD
Atomoxetine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000288	0.0048	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000282	0.0047	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000278	0.00462	CbGeAlD
Atomoxetine—Phenprocoumon—ALB—acquired immunodeficiency syndrome	0.000252	0.076	CrCbGaD
Atomoxetine—Fluoxetine—ALB—acquired immunodeficiency syndrome	0.000245	0.0739	CrCbGaD
Atomoxetine—HTR2A—brain—acquired immunodeficiency syndrome	0.000242	0.00403	CbGeAlD
Atomoxetine—Warfarin—ALB—acquired immunodeficiency syndrome	0.000223	0.0674	CrCbGaD
Atomoxetine—CYP2D6—brain—acquired immunodeficiency syndrome	0.00022	0.00367	CbGeAlD
Atomoxetine—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000879	CcSEcCtD
Atomoxetine—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000879	CcSEcCtD
Atomoxetine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000207	0.000877	CcSEcCtD
Atomoxetine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000207	0.000876	CcSEcCtD
Atomoxetine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000207	0.000876	CcSEcCtD
Atomoxetine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000207	0.000876	CcSEcCtD
Atomoxetine—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000206	0.000872	CcSEcCtD
Atomoxetine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000205	0.000871	CcSEcCtD
Atomoxetine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000205	0.000869	CcSEcCtD
Atomoxetine—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000205	0.000868	CcSEcCtD
Atomoxetine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000205	0.000868	CcSEcCtD
Atomoxetine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000204	0.000866	CcSEcCtD
Atomoxetine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000204	0.000866	CcSEcCtD
Atomoxetine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000204	0.000865	CcSEcCtD
Atomoxetine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000204	0.000864	CcSEcCtD
Atomoxetine—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000863	CcSEcCtD
Atomoxetine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000203	0.000861	CcSEcCtD
Atomoxetine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.00086	CcSEcCtD
Atomoxetine—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000203	0.000859	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000202	0.000858	CcSEcCtD
Atomoxetine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000202	0.000857	CcSEcCtD
Atomoxetine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000202	0.000857	CcSEcCtD
Atomoxetine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000202	0.000856	CcSEcCtD
Atomoxetine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000201	0.000854	CcSEcCtD
Atomoxetine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000201	0.000853	CcSEcCtD
Atomoxetine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000201	0.000853	CcSEcCtD
Atomoxetine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000851	CcSEcCtD
Atomoxetine—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000851	CcSEcCtD
Atomoxetine—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000851	CcSEcCtD
Atomoxetine—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.0002	0.000848	CcSEcCtD
Atomoxetine—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000848	CcSEcCtD
Atomoxetine—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.000846	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.000845	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000199	0.000843	CcSEcCtD
Atomoxetine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000198	0.000841	CcSEcCtD
Atomoxetine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000198	0.000841	CcSEcCtD
Atomoxetine—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000841	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.00084	CcSEcCtD
Atomoxetine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000198	0.00084	CcSEcCtD
Atomoxetine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000197	0.000835	CcSEcCtD
Atomoxetine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000197	0.000835	CcSEcCtD
Atomoxetine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.000834	CcSEcCtD
Atomoxetine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.000834	CcSEcCtD
Atomoxetine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.000834	CcSEcCtD
Atomoxetine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000196	0.000832	CcSEcCtD
Atomoxetine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000196	0.00083	CcSEcCtD
Atomoxetine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000196	0.00083	CcSEcCtD
Atomoxetine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000195	0.000829	CcSEcCtD
Atomoxetine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.000828	CcSEcCtD
Atomoxetine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000195	0.000826	CcSEcCtD
Atomoxetine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000195	0.000826	CcSEcCtD
Atomoxetine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000194	0.000825	CcSEcCtD
Atomoxetine—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000194	0.000823	CcSEcCtD
Atomoxetine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000193	0.00082	CcSEcCtD
Atomoxetine—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000819	CcSEcCtD
Atomoxetine—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000819	CcSEcCtD
Atomoxetine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000819	CcSEcCtD
Atomoxetine—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000816	CcSEcCtD
Atomoxetine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000192	0.000814	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000813	CcSEcCtD
Atomoxetine—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000191	0.000812	CcSEcCtD
Atomoxetine—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000807	CcSEcCtD
Atomoxetine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00019	0.000804	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.000804	CcSEcCtD
Atomoxetine—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.000803	CcSEcCtD
Atomoxetine—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000189	0.000802	CcSEcCtD
Atomoxetine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000189	0.000801	CcSEcCtD
Atomoxetine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000189	0.000801	CcSEcCtD
Atomoxetine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000189	0.000801	CcSEcCtD
Atomoxetine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.0008	CcSEcCtD
Atomoxetine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000188	0.000798	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000188	0.000798	CcSEcCtD
Atomoxetine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.000798	CcSEcCtD
Atomoxetine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000188	0.000796	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000188	0.000796	CcSEcCtD
Atomoxetine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.000795	CcSEcCtD
Atomoxetine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000188	0.000795	CcSEcCtD
Atomoxetine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000187	0.000795	CcSEcCtD
Atomoxetine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000187	0.000792	CcSEcCtD
Atomoxetine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.000792	CcSEcCtD
Atomoxetine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000186	0.000789	CcSEcCtD
Atomoxetine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000186	0.000788	CcSEcCtD
Atomoxetine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000186	0.000788	CcSEcCtD
Atomoxetine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000186	0.000788	CcSEcCtD
Atomoxetine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000186	0.000788	CcSEcCtD
Atomoxetine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000185	0.000787	CcSEcCtD
Atomoxetine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000185	0.000784	CcSEcCtD
Atomoxetine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000185	0.000783	CcSEcCtD
Atomoxetine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000781	CcSEcCtD
Atomoxetine—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000781	CcSEcCtD
Atomoxetine—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000781	CcSEcCtD
Atomoxetine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000184	0.00078	CcSEcCtD
Atomoxetine—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000779	CcSEcCtD
Atomoxetine—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000778	CcSEcCtD
Atomoxetine—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000183	0.000777	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000776	CcSEcCtD
Atomoxetine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000183	0.000775	CcSEcCtD
Atomoxetine—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000773	CcSEcCtD
Atomoxetine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000182	0.000771	CcSEcCtD
Atomoxetine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000182	0.000771	CcSEcCtD
Atomoxetine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.00077	CcSEcCtD
Atomoxetine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000182	0.00077	CcSEcCtD
Atomoxetine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000181	0.000768	CcSEcCtD
Atomoxetine—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000181	0.000767	CcSEcCtD
Atomoxetine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00018	0.000764	CcSEcCtD
Atomoxetine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00018	0.000764	CcSEcCtD
Atomoxetine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00018	0.000763	CcSEcCtD
Atomoxetine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00018	0.000763	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00018	0.000762	CcSEcCtD
Atomoxetine—Rash—Stavudine—acquired immunodeficiency syndrome	0.00018	0.000761	CcSEcCtD
Atomoxetine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000179	0.000761	CcSEcCtD
Atomoxetine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000179	0.000761	CcSEcCtD
Atomoxetine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000179	0.00076	CcSEcCtD
Atomoxetine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000179	0.000759	CcSEcCtD
Atomoxetine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000179	0.000759	CcSEcCtD
Atomoxetine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000178	0.000756	CcSEcCtD
Atomoxetine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000178	0.000756	CcSEcCtD
Atomoxetine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000178	0.000754	CcSEcCtD
Atomoxetine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000178	0.000754	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000178	0.000754	CcSEcCtD
Atomoxetine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000178	0.000753	CcSEcCtD
Atomoxetine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000177	0.00075	CcSEcCtD
Atomoxetine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000177	0.000749	CcSEcCtD
Atomoxetine—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000177	0.000748	CcSEcCtD
Atomoxetine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000176	0.000745	CcSEcCtD
Atomoxetine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000744	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000175	0.000743	CcSEcCtD
Atomoxetine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000175	0.000743	CcSEcCtD
Atomoxetine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000175	0.000742	CcSEcCtD
Atomoxetine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000738	CcSEcCtD
Atomoxetine—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000737	CcSEcCtD
Atomoxetine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000173	0.000735	CcSEcCtD
Atomoxetine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.000733	CcSEcCtD
Atomoxetine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000733	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—acquired immunodeficiency syndrome	0.000172	0.052	CrCbGaD
Atomoxetine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.000729	CcSEcCtD
Atomoxetine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.000729	CcSEcCtD
Atomoxetine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000172	0.000728	CcSEcCtD
Atomoxetine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000171	0.000727	CcSEcCtD
Atomoxetine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000171	0.000725	CcSEcCtD
Atomoxetine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000171	0.000724	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00017	0.000721	CcSEcCtD
Atomoxetine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00017	0.000719	CcSEcCtD
Atomoxetine—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.000718	CcSEcCtD
Atomoxetine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000169	0.000718	CcSEcCtD
Atomoxetine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000169	0.000717	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.000715	CcSEcCtD
Atomoxetine—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000714	CcSEcCtD
Atomoxetine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.00071	CcSEcCtD
Atomoxetine—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000167	0.000709	CcSEcCtD
Atomoxetine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000167	0.000706	CcSEcCtD
Atomoxetine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000705	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.000704	CcSEcCtD
Atomoxetine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.000703	CcSEcCtD
Atomoxetine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000165	0.000701	CcSEcCtD
Atomoxetine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000165	0.0007	CcSEcCtD
Atomoxetine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.000698	CcSEcCtD
Atomoxetine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000165	0.000698	CcSEcCtD
Atomoxetine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000165	0.000698	CcSEcCtD
Atomoxetine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000697	CcSEcCtD
Atomoxetine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000697	CcSEcCtD
Atomoxetine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000164	0.000694	CcSEcCtD
Atomoxetine—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.000691	CcSEcCtD
Atomoxetine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000163	0.00069	CcSEcCtD
Atomoxetine—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000161	0.000683	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.000682	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000678	CcSEcCtD
Atomoxetine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000678	CcSEcCtD
Atomoxetine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000677	CcSEcCtD
Atomoxetine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000673	CcSEcCtD
Atomoxetine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000159	0.000672	CcSEcCtD
Atomoxetine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000671	CcSEcCtD
Atomoxetine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000671	CcSEcCtD
Atomoxetine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000157	0.000668	CcSEcCtD
Atomoxetine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000157	0.000667	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000157	0.000667	CcSEcCtD
Atomoxetine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000157	0.000666	CcSEcCtD
Atomoxetine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000156	0.000662	CcSEcCtD
Atomoxetine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000156	0.000662	CcSEcCtD
Atomoxetine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000156	0.000661	CcSEcCtD
Atomoxetine—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000156	0.000659	CcSEcCtD
Atomoxetine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000155	0.000657	CcSEcCtD
Atomoxetine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.000652	CcSEcCtD
Atomoxetine—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000154	0.000651	CcSEcCtD
Atomoxetine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000648	CcSEcCtD
Atomoxetine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000153	0.000647	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.000647	CcSEcCtD
Atomoxetine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.000646	CcSEcCtD
Atomoxetine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000152	0.000645	CcSEcCtD
Atomoxetine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000645	CcSEcCtD
Atomoxetine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000645	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.000642	CcSEcCtD
Atomoxetine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000641	CcSEcCtD
Atomoxetine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000641	CcSEcCtD
Atomoxetine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000149	0.000633	CcSEcCtD
Atomoxetine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000149	0.000631	CcSEcCtD
Atomoxetine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000624	CcSEcCtD
Atomoxetine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000624	CcSEcCtD
Atomoxetine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000147	0.000623	CcSEcCtD
Atomoxetine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000621	CcSEcCtD
Atomoxetine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000621	CcSEcCtD
Atomoxetine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000146	0.00062	CcSEcCtD
Atomoxetine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000146	0.000617	CcSEcCtD
Atomoxetine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000145	0.000615	CcSEcCtD
Atomoxetine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000145	0.000615	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000613	CcSEcCtD
Atomoxetine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000144	0.000611	CcSEcCtD
Atomoxetine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000144	0.00061	CcSEcCtD
Atomoxetine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000604	CcSEcCtD
Atomoxetine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000595	CcSEcCtD
Atomoxetine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000592	CcSEcCtD
Atomoxetine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000592	CcSEcCtD
Atomoxetine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000138	0.000586	CcSEcCtD
Atomoxetine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000585	CcSEcCtD
Atomoxetine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000138	0.000583	CcSEcCtD
Atomoxetine—Nortriptyline—ALB—acquired immunodeficiency syndrome	0.000138	0.0415	CrCbGaD
Atomoxetine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000137	0.000581	CcSEcCtD
Atomoxetine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000137	0.000581	CcSEcCtD
Atomoxetine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000137	0.00058	CcSEcCtD
Atomoxetine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000578	CcSEcCtD
Atomoxetine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000577	CcSEcCtD
Atomoxetine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000133	0.000563	CcSEcCtD
Atomoxetine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000132	0.000561	CcSEcCtD
Atomoxetine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000132	0.000558	CcSEcCtD
Atomoxetine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000131	0.000556	CcSEcCtD
Atomoxetine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000131	0.000556	CcSEcCtD
Atomoxetine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000556	CcSEcCtD
Atomoxetine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000553	CcSEcCtD
Atomoxetine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000129	0.000548	CcSEcCtD
Atomoxetine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000539	CcSEcCtD
Atomoxetine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000537	CcSEcCtD
Atomoxetine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.000537	CcSEcCtD
Atomoxetine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.00053	CcSEcCtD
Atomoxetine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000124	0.000524	CcSEcCtD
Atomoxetine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000519	CcSEcCtD
Atomoxetine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000122	0.000519	CcSEcCtD
Atomoxetine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000514	CcSEcCtD
Atomoxetine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000514	CcSEcCtD
Atomoxetine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000513	CcSEcCtD
Atomoxetine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000511	CcSEcCtD
Atomoxetine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000118	0.000499	CcSEcCtD
Atomoxetine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000117	0.000495	CcSEcCtD
Atomoxetine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000495	CcSEcCtD
Atomoxetine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000495	CcSEcCtD
Atomoxetine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000492	CcSEcCtD
Atomoxetine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000114	0.000485	CcSEcCtD
Atomoxetine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000476	CcSEcCtD
Atomoxetine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000472	CcSEcCtD
Atomoxetine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000472	CcSEcCtD
Atomoxetine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000469	CcSEcCtD
Atomoxetine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.000466	CcSEcCtD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000107	0.00215	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000107	0.00214	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000106	0.00212	CbGpPWpGaD
Atomoxetine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000105	0.000445	CcSEcCtD
Atomoxetine—HTR2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000105	0.0021	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000105	0.0021	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000101	0.00203	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000101	0.00202	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.0001	0.00201	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.99e-05	0.002	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.98e-05	0.002	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.91e-05	0.00199	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.91e-05	0.00199	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.91e-05	0.00199	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.83e-05	0.00197	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.8e-05	0.00197	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.78e-05	0.00196	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.71e-05	0.00195	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.51e-05	0.00191	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.51e-05	0.00191	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.5e-05	0.00191	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.44e-05	0.00189	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.44e-05	0.00189	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.43e-05	0.00189	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.39e-05	0.00188	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.32e-05	0.00187	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.29e-05	0.00186	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.24e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.24e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.23e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.22e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.2e-05	0.00185	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.2e-05	0.00185	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.19e-05	0.00184	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.07e-05	0.00182	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.06e-05	0.00182	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.03e-05	0.00181	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.99e-05	0.0018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.8e-05	0.00177	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.56e-05	0.00172	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.49e-05	0.0017	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.49e-05	0.0017	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.4e-05	0.00169	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.34e-05	0.00167	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.32e-05	0.00167	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.31e-05	0.00167	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.24e-05	0.00165	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.16e-05	0.00164	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.99e-05	0.0016	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.99e-05	0.0016	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.81e-05	0.00157	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.81e-05	0.00157	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.6e-05	0.00152	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.45e-05	0.00149	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.36e-05	0.00148	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.23e-05	0.00145	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.18e-05	0.00144	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.15e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.03e-05	0.00141	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7e-05	0.00141	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7e-05	0.00141	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7e-05	0.0014	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.84e-05	0.00137	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	6.68e-05	0.00134	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.67e-05	0.00134	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.52e-05	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.47e-05	0.0013	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.47e-05	0.0013	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	6.46e-05	0.0013	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.39e-05	0.00128	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.33e-05	0.00127	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.3e-05	0.00126	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.19e-05	0.00124	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.08e-05	0.00122	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.08e-05	0.00122	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.07e-05	0.00122	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.94e-05	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.94e-05	0.00119	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.86e-05	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.79e-05	0.00116	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.77e-05	0.00116	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.74e-05	0.00115	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.72e-05	0.00115	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.00115	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.7e-05	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.67e-05	0.00114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.58e-05	0.00112	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.55e-05	0.00111	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.49e-05	0.0011	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.49e-05	0.0011	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.47e-05	0.0011	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.45e-05	0.00109	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.45e-05	0.00109	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.39e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.37e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.37e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.37e-05	0.00108	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.36e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.33e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.33e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.33e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.33e-05	0.00107	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.33e-05	0.00107	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.24e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.22e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.22e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.19e-05	0.00104	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.15e-05	0.00103	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.04e-05	0.00101	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.96e-05	0.000996	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.92e-05	0.000988	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.88e-05	0.000979	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.88e-05	0.000979	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.84e-05	0.000972	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.84e-05	0.000972	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.82e-05	0.000968	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.8e-05	0.000963	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.74e-05	0.000951	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.74e-05	0.000951	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.63e-05	0.000928	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.4e-05	0.000883	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.23e-05	0.000848	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.21e-05	0.000844	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.17e-05	0.000836	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.00082	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.06e-05	0.000814	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.04e-05	0.000811	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.04e-05	0.000811	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.000808	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.02e-05	0.000807	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4e-05	0.000802	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	3.98e-05	0.000798	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.97e-05	0.000797	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.96e-05	0.000794	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.96e-05	0.000794	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.91e-05	0.000785	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.82e-05	0.000767	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.71e-05	0.000745	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.68e-05	0.000739	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.68e-05	0.000739	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.67e-05	0.000736	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	3.66e-05	0.000734	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.66e-05	0.000734	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.65e-05	0.000733	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.65e-05	0.000733	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.65e-05	0.000733	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.63e-05	0.000728	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.61e-05	0.000724	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.59e-05	0.000721	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.59e-05	0.000721	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.58e-05	0.000718	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.55e-05	0.000713	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.51e-05	0.000704	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.51e-05	0.000704	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.44e-05	0.000689	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.44e-05	0.000689	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.39e-05	0.00068	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	3.38e-05	0.000679	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.36e-05	0.000675	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.34e-05	0.000671	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.32e-05	0.000666	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.32e-05	0.000666	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.29e-05	0.000661	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.28e-05	0.000659	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.25e-05	0.000652	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.24e-05	0.000651	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.17e-05	0.000637	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.12e-05	0.000626	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.12e-05	0.000626	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.11e-05	0.000624	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.09e-05	0.000621	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.08e-05	0.000618	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.07e-05	0.000615	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.04e-05	0.00061	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.01e-05	0.000604	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.98e-05	0.000598	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.000595	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.91e-05	0.000584	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.89e-05	0.00058	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.88e-05	0.000578	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.88e-05	0.000578	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.86e-05	0.000574	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.86e-05	0.000574	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.8e-05	0.000562	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.8e-05	0.000562	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.73e-05	0.000549	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.71e-05	0.000544	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.69e-05	0.00054	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.61e-05	0.000525	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.58e-05	0.000517	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.51e-05	0.000504	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.5e-05	0.000501	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.46e-05	0.000494	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.39e-05	0.00048	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.37e-05	0.000476	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.36e-05	0.000473	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.34e-05	0.000469	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.26e-05	0.000453	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.19e-05	0.00044	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.18e-05	0.000437	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.17e-05	0.000435	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.16e-05	0.000433	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.14e-05	0.00043	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.14e-05	0.000429	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.13e-05	0.000428	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.13e-05	0.000427	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.12e-05	0.000426	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.12e-05	0.000426	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.11e-05	0.000424	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.1e-05	0.000421	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.07e-05	0.000415	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.03e-05	0.000408	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.98e-05	0.000396	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.96e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.96e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.93e-05	0.000388	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.92e-05	0.000385	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.92e-05	0.000385	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.88e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.84e-05	0.00037	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.84e-05	0.00037	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.82e-05	0.000365	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.61e-05	0.000324	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.59e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000314	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.45e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.42e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.4e-05	0.000281	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.36e-05	0.000273	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.000254	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000248	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.14e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000228	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000227	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.13e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.11e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.41e-06	0.000169	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.36e-06	0.000168	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.3e-06	0.000146	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.26e-06	0.000146	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	6.94e-06	0.000139	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.71e-06	0.000135	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.66e-06	0.000134	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.52e-06	0.000131	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	6.38e-06	0.000128	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.94e-06	9.91e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.29e-06	8.61e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.17e-06	8.37e-05	CbGpPWpGaD
